{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:27:41Z","timestamp":1792704461953,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01193-x","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T14:14:43Z","timestamp":1766931283000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential"],"prefix":"10.1007","volume":"21","author":[{"given":"Yeokyeong","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyehyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwook","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Byung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-6007","authenticated-orcid":false,"given":"Seung-Mo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"1193_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384314","volume":"11","author":"J Su","year":"2024","unstructured":"Su J, Liang Y, He X. Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019. Front Med (Lausanne). 2024;11:1384314.","journal-title":"Front Med (Lausanne)"},{"key":"1193_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1193_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"1193_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jhep.2025.03.013","volume":"83","author":"C Yoo","year":"2025","unstructured":"Yoo C, Saborowski A, Hyung J, Wenzel P, Kim I, Wege H, et al. Liposomal irinotecan for previously treated patients with biliary tract cancer: a pooled analysis of NIFTY and NALIRICC trials. J Hepatol. 2025;83:909\u201316.","journal-title":"J Hepatol"},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol"},{"key":"1193_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O Tureci","year":"2011","unstructured":"Tureci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83\u201392.","journal-title":"Gene"},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380\u201390.","journal-title":"Mol Cell Biol"},{"key":"1193_CR9","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624\u201334.","journal-title":"Clin Cancer Res"},{"key":"1193_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655\u201368.","journal-title":"Lancet"},{"key":"1193_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"1193_CR12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/onc.2012.151","volume":"32","author":"E Guerra","year":"2013","unstructured":"Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32:1594\u2013600.","journal-title":"Oncogene"},{"key":"1193_CR13","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1073\/pnas.1905384117","volume":"117","author":"EC Hsu","year":"2020","unstructured":"Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc Natl Acad Sci USA. 2020;117:2032\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1193_CR14","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3390\/cancers14174137","volume":"14","author":"J Svec","year":"2022","unstructured":"Svec J, Stastna M, Janeckova L, Hrckulak D, Vojtechova M, Onhajzer J, et al. TROP2 represents a negative prognostic factor in colorectal adenocarcinoma and its expression is associated with features of epithelial-mesenchymal transition and invasiveness. Cancers (Basel). 2022;14:4137.","journal-title":"Cancers (Basel)."},{"key":"1193_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222\u201333.","journal-title":"Oncogene"},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, Hoflmayer D, Volkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358.","journal-title":"Pathobiology"},{"key":"1193_CR17","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"1193_CR18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148\u201356.","journal-title":"Ann Oncol"},{"key":"1193_CR19","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42:2860\u201372.","journal-title":"J Clin Oncol"},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Flechon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474\u201385.","journal-title":"J Clin Oncol"},{"key":"1193_CR21","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30:3709\u201316.","journal-title":"Nat Med"},{"key":"1193_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pathol.2016.04.002","volume":"48","author":"A Bychkov","year":"2016","unstructured":"Bychkov A, Sampatanukul P, Shuangshoti S, Keelawat S. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology. 2016;48:425\u201333.","journal-title":"Pathology"},{"key":"1193_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105049","volume":"10","author":"V Angerilli","year":"2025","unstructured":"Angerilli V, Sacchi D, Rizzato M, Gasparello J, Ceccon C, Sabbadin M, et al. Claudin 18.2: a promising actionable target in biliary tract cancers. ESMO Open. 2025;10:105049.","journal-title":"ESMO Open"},{"key":"1193_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/his.15407","volume":"86","author":"MN Kinzler","year":"2025","unstructured":"Kinzler MN, Gretser S, Schulze F, Bankov K, Abedin N, Bechstein WO, et al. Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre. Histopathology. 2025;86:640\u20136.","journal-title":"Histopathology"},{"key":"1193_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/his.14358","volume":"79","author":"M Iwaya","year":"2021","unstructured":"Iwaya M, Hayashi H, Nakajima T, Matsuda K, Kinugawa Y, Tobe Y, et al. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy. Histopathology. 2021;79:227\u201337.","journal-title":"Histopathology"},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, Luo SX, Zhuang ZX, Wang ZN, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338.","journal-title":"Lancet Oncol"},{"key":"1193_CR27","doi-asserted-by":"publisher","first-page":"TPS3163","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3163","volume":"42","author":"AG Raufi","year":"2024","unstructured":"Raufi AG, Goyal L, Smyth E, Szekeres P, Petrone M, Hobson R, et al. CLARITY-PanTumor01: a phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. J Clin Oncol. 2024;42:TPS3163.","journal-title":"J Clin Oncol"},{"key":"1193_CR28","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochimica et Biophysica Acta (BBA). 2023;1878:188902.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1193_CR29","unstructured":"University of Kansas Medical Center. Sacituzumab govitecan for the treatment for patients with locally advanced, recurrent, or metastatic cholangiocarcinoma. US National Library of Medicine. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06178588. Accessed 27 June 2025."},{"key":"1193_CR30","unstructured":"AstraZeneca. Study of Dato\u2011DxD as monotherapy and in combination with anti\u2011cancer agents in patients with advanced solid tumours (TROPION\u2011PanTumor03). US National Library of Medicine. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05489211. Accessed 27 June 2025."},{"key":"1193_CR31","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino MC, Sands J, Paz-Ares L, Lisberg A, Johnson M, P\u00e9rol M, et al. PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. J Thorac Oncol. 2024;19:S2\u20133.","journal-title":"J Thorac Oncol"},{"key":"1193_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/ajcp\/aqae161","volume":"163","author":"KB Case","year":"2025","unstructured":"Case KB, Martini DJ, Dababneh MN, Bidot S, Nazha B, Brown J, et al. Trop-2 and ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. Am J Clin Pathol. 2025;163:618\u201328.","journal-title":"Am J Clin Pathol"},{"key":"1193_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010087","volume":"23","author":"R Erber","year":"2021","unstructured":"Erber R, Spoerl S, Mamilos A, Krupar R, Hartmann A, Ruebner M, et al. Impact of spatially heterogeneous Trop-2 expression on prognosis in oral squamous cell carcinoma. Int J Mol Sci. 2021;23:87.","journal-title":"Int J Mol Sci"},{"key":"1193_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13101445","volume":"13","author":"E Liatsou","year":"2023","unstructured":"Liatsou E, Schizas D, Frountzas M. The impact of trophoblast cell-surface antigen 2 expression on the survival of patients with gastrointestinal tumors: a systematic review. J Pers Med. 2023;13:1445.","journal-title":"J Pers Med"},{"key":"1193_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5604\/16652681.1184223","volume":"15","author":"K Sawanyawisuth","year":"2016","unstructured":"Sawanyawisuth K, Tantapotinan N, Wongkham C, Riggins GJ, Kraiklang R, Wongkham S, et al. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol. 2016;15:71\u201381.","journal-title":"Ann Hepatol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01193-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:10Z","timestamp":1771692430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01193-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Baek-Yeol Ryoo, Kyu-Pyo Kim, Inkeun Park, Dong-Wan Seo, Do Hyun Park, Tae Jun Song, Dongwook Oh, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, and Changhoon Yoo declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) of Asan Medical Center in accordance with the ethical standards of the institutional research committee and the Declaration of Helsinki. A waiver of informed consent for this retrospective study was granted by the IRB (IRB no. 2024-0242).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent from the patients was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data supporting the findings of this study are available within the paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization\u2014Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Seung-Mo Hong, and Changhoon Yoo; data curation\u2014Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Baek-Yeol Ryoo, Kyu-Pyo Kim, Inkeun Park, Dong-Wan Seo, Do Hyun Park, Tae Jun Song, Dongwook Oh, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, and Changhoon Yoo; formal analysis\u2014Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Seung-Mo Hong, and Changhoon Yoo; methodology\u2014Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Seung-Mo Hong, and Changhoon Yoo; supervision\u2014Seung-Mo Hong and Changhoon Yoo; visualization\u2014Yeokyeong Shin and Jinho Shin; writing\u2014original draft\u2014Yeokyeong Shin; writing\u2014review and editing\u2014Yeokyeong Shin, Jinho Shin, Hyehyun Jeong, Baek-Yeol Ryoo, Kyu-Pyo Kim, Inkeun Park, Dong-Wan Seo, Do Hyun Park, Tae Jun Song, Dongwook Oh, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, and Changhoon Yoo.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}